Drug Trial Radar · NCT06885567
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 2025
Primary completion
Jul 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- BeyondBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.
Conditions
- Alzheimer Disease
- Alzheimer' Disease
Interventions
BEY2153Drug
Participants administer once daily, PO, 26 weeks
PlaceboDrug
Participants administer once daily, PO, 26 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline until 4 weeks after the end of treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea
SMG-SNU Boramae Medical Center
Seoul, South Korea
Yeouido St. Mary's Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.